Investment Thesis

.

Competitive Moat

characterized by strong network effects and significant intangible assets. Its vast database, comprising real-world patient data and analytics, creates a formidable barrier for new entrants, as the value of its services increases with the size of its data pool. Additionally, IQVIA's established relationships with pharmaceutical and biotech companies further entrench its position, allowing for high switching costs. Over the next 5-10 years, this moat appears durable, though competitive threats from emerging analytics firms and in-house solutions from large pharmaceutical companies could pose challenges.

Growth Engine

Future revenue growth for IQVIA is anticipated to arise from the expanding total addressable market (TAM) in healthcare analytics, projected to grow significantly as the industry leans more heavily on data for decision-making. The company is well-positioned to capitalize on organic growth through its Technology & Analytics Solutions segment, which is increasingly in demand. Additionally, geographic expansion into emerging markets and new product lines in virtual clinical trials and real-world evidence solutions will further drive growth. Market share is expected to improve as IQVIA continues to innovate and adapt to the evolving needs of its clients.